Literature DB >> 21139899

Pleomorphic sarcoma metastatic to the duodenum?

Fabio R Tavora1, Allen P Burke.   

Abstract

Entities:  

Year:  2009        PMID: 21139899      PMCID: PMC2994442          DOI: 10.4081/rt.2009.e5

Source DB:  PubMed          Journal:  Rare Tumors        ISSN: 2036-3605


× No keyword cloud information.
We read with interest Hawasli et al. report of a pleomorphic sarcoma metastatic to the left atrium.[1] However, we suspect that the true site of origin is unknown, and may in fact be the heart. There are several reasons for this: the histological appearance is similar to left atrial tumors that have already been reported;[2] the left atrium, is the most common site of cardiac pleomorphic sarcoma; all metastatic sarcomas to the heart have been in the right atrium or ventricle or have involved myocardium and/or pericardium; [3,4] the tumor appears to have been present in the heart at the time of intestinal resection, as the angiographic findings suggest, as well as the large size of the valve tumor (9 cm); tumors of such histology are very uncommon in the duodenum; histopathological findings of the duodenal specimen are not presented. At the very least, we believe that it is unknown which of the two sites is primary. For this reason, we believe that the very rare scenario of metastatic sarcoma presenting as a left atrial mass is still not demonstrated convincingly.
  3 in total

1.  Primary sarcomas of the heart.

Authors:  A P Burke; D Cowan; R Virmani
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

2.  Metastatic pleomorphic sarcoma to left atrium.

Authors:  Ammar H Hawasli; Rachael Cayce; Trung Luong; Evelyn Taiwo; Michael N Feliciano; Sharon C Reimold; John M Dimaio; Barbara B Haley
Journal:  Rare Tumors       Date:  2009-07-22

3.  Cardiac metastases from soft-tissue sarcomas.

Authors:  D E Hallahan; N J Vogelzang; K M Borow; D G Bostwick; M A Simon
Journal:  J Clin Oncol       Date:  1986-11       Impact factor: 44.544

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.